MISSION Leading the fight to treat and cure ALS through global research and nationwide advocacy, while also empowering people with Lou Gehrig’s Disease and their families to live fuller lives by providing them with compassionate care and support.

VISION Create a world without ALS
MESSAGE FROM JANE H. GILBERT

For those of us engaged in the fight against amyotrophic lateral sclerosis (ALS), nothing short of effective treatments and a cure will be considered a victory. The people who have been diagnosed, the families and friends who love and care for them and the millions who have already lost someone to ALS are looking to The ALS Association and the scientific community to lead the way in the quest to put an end to this terrible disease.

For decades, this journey has been slow and tedious; however, reason for hope is on the horizon. Thanks to those who have partnered with and supported The ALS Association, there are many areas where encouraging progress indicates tangible results in the near future. As you will read in our financial report, The Association has been a good steward of your philanthropic contributions. This past year, 80 cents of every dollar you donated went to support programs serving the ALS community.

Our ratios reflect an improved spending position thanks to more investment in research and realizing more than $6 million in donated media revenue—an area which will continue in future years, as we push forward to meet our goal of increased awareness for ALS.

Building on the discovery of the role of the C9orf72 gene mutation, which was published by two different ALS Association-funded research teams, many scientists across the globe have begun to explore new areas of ALS research. And, the focus on ALS Research during the past year has created unprecedented excitement among members of the scientific community.

The ALS Association’s nationwide network of chapters offer services to people with ALS and their families, and local certified centers and clinics provide multidisciplinary care that is the recognized gold standard for treating ALS patients. A growing body of evidence indicates that this type of coordinated care not only helps people manage symptoms but may also increase life expectancy.

The Association’s public policy efforts have continued to successfully increase congressional support for ALS research funding at a time when many government programs have been reduced or eliminated. This achievement is due in great part to the active participation of advocates who come to Washington, D.C., each May during the National ALS Advocacy Day and Public Policy Conference. Advocates learn about the current initiatives and take their message to lawmakers on Capitol Hill. It is personal stories about living with the disease, along with a consistent, coordinated message that makes this approach so effective.

While ALS still must compete for public attention with causes that impact many more people, no disease is more devastating or deserving of public support. The Association was able to reach millions of Americans through a successful public service announcement campaign, an invigorated public media outreach and the continually growing Walk to Defeat ALS® program. Altogether, the ALS message reached more people this year than ever before.

All of these successes, however, do not begin to address the depth and breadth of the need. People continue to be diagnosed. Families and their loved ones still suffer from the progressive nature of this disease. And the cruelest fact of all, every day more and more Americans die of ALS.

This is totally unacceptable to me personally and as President and CEO of The ALS Association. This is why I begin each day with a personal challenge: What can I do today to move us closer to finding answers? How can I help the nation become more involved in the fight to discover effective treatments? What leadership decisions can I make to guide The ALS Association toward our ultimate vision of creating a world without ALS?

With your support, I will continue to ask these questions, and to the best of my ability, work to provide smarter, faster, and more effective answers. This is my promise. This is my pledge. This is my purpose.

My most sincere thanks and very best regards,

Jane H. Gilbert
President and Chief Executive Officer
The ALS Association
The feeling that now is the time to capitalize on the growing understanding of the disease’s causes wasn’t lost on Capitol Hill. Just three days after people with ALS and their family members met with members of Congress at the National ALS Advocacy Day and Public Policy Conference, the U.S. House of Representatives passed legislation to provide $7.5 million in funding for the ALS Research Program at the Department of Defense—a 17 percent increase over the previous year, remarkable in an era of financial austerity. Meanwhile, from baseball stadiums to fundraising walks, and through television public service announcements and social media, more people than ever before were learning about Lou Gehrig’s Disease. Many of them were joining robust local and national endeavors to assist people living with ALS and supporting the goal of bringing an end to the disease once and for all.

Driving these efforts, as has been the case since our founding in 1985, was The ALS Association—the only national nonprofit organization engaged in every aspect of the fight: coordinating and funding a global research program; advocating for policies and financial support to enhance the research effort and improve the lives of people living with ALS and their families; delivering state-of-the-art, multidisciplinary care through ALS Association Certified Centers of Excellence and clinics; providing education and resources to assist people with ALS and their families through their ordeal; and promoting awareness of and public support for Lou Gehrig’s Disease.

In FYE 2013, The Association gained steam in all of these areas—not the least of which was to fuel an ever-increasing pace of discovery that is moving us closer to a world without this devastating disease.

RESEARCH INVESTMENTS PAYING DIVIDENDS

The Association’s Translational Research Advancing Therapy for ALS TREAT ALS™ program serves as a catalyst for a systematic and comprehensive effort to solve the mysteries surrounding ALS and bring effective new treatments to people who urgently need them. It does so by funding a coordinated global research effort that helps to draw top researchers to the field and enables exciting new hypotheses to be pursued; by forging partnerships among researchers and with the government and private industry; and by hastening the pace at which promising laboratory discoveries can be translated into new therapies.
and moved through clinical trials. As of January 31, 2013, there were 97 active projects funded by The Association for a total commitment of more than $15.5 million. And by investing in a better understanding of the genetic and molecular causes of Lou Gehrig’s Disease, The Association is paving the way for exciting developments that are beginning to bear fruit.

**Capitalizing on Genetic Discoveries.** One of the most closely watched developments in ALS research in FYE 2013 stemmed from the discovery in late 2011 by two independent research teams that mutations in the C9orf72 gene are associated with ALS, as well as frontotemporal dementia (FTD). The announcement led to the recognition that the mutations in this gene are the single most common known cause of ALS throughout the world, accounting for approximately 35 percent of familial cases and six percent of sporadic (non-inherited) cases, as well as about one-fourth of FTD cases. Researchers funded by The Association have led the way in characterizing the nature of the gene mutation, building the first cellular and animal models of the gene, and determining the consequences of the mutation for motor neurons and surrounding cells. A further understanding of how the mutated C9orf72 gene causes ALS will likely reveal important new pathways that control motor neuron health and point to multiple targets for new drug therapies. In addition to fueling continued efforts to learn more about the gene’s role in Lou Gehrig’s Disease, The ALS Association is contributing to scientific discussions on the topic. In October 2012, The Association presented a symposium at the annual meeting of the Society of Neuroscience—the largest gathering of neuroscientists in the world—on the latest understanding of the C9orf72 gene. As researchers homed in on the C9orf72 gene, the biology of several other ALS genes was also the focus of important new discoveries. Similarly functioning proteins produced by the genes FUS and TDP-43 have been linked to familial ALS and are believed to be involved in the disease, either by causing a new toxic response or through loss of the proteins’ normal function. ALS Association-funded researchers made a number of intriguing discoveries surrounding these proteins in FYE 2013. Among them was the observation that the FUS protein physically interacts with a protein called SMN, whose absence causes another motor neuron disease, spinal muscular atrophy. This interaction suggests that the two diseases may be linked at the cellular level. Other researchers funded by The Association discovered that the FUS and TDP-43 proteins bind to some of the same genes, raising the likelihood that these genes may be especially important in understanding how mutations in FUS and TDP-43 cause ALS. Finally, ALS Association-funded researchers reported that a cell rescue strategy may go awry when TDP-43 is mutated, which could mean that removal of the enzyme at the heart of that strategy would be therapeutic.

Elsewhere, ALS Association-funded researchers showed that mutations in a transport gene called profilin appear to account for one to two percent of inherited ALS cases, highlighting the importance of the transport system within the cell for motor neuron health. Two ALS Association-funded groups also made advances in understanding factors influencing the age of onset of ALS—discoveries that may lead to ways to delay onset by influencing these pathways.

**Biomarkers Bring Valuable Tool to Clinical Trials.** The effort to accelerate the process of taking promising drugs to clinical trials is advancing on multiple fronts. One involves the development of biomarkers—substances in the blood or cerebrospinal fluid that change with the disease state and thus can be used both for earlier diagnosis and the tracking of response to a therapy, facilitating
more decisive clinical trials of new drugs. The Association is funding a consortium effort, enlisting leading researchers and biotech companies in the search for reliable biomarkers of ALS. In FYE 2013, two laboratories funded by The Association announced their discoveries of potential biomarkers, which will now be refined and evaluated further for their potential to be used in clinical trials.

TREAT ALS Accelerates Development of New Therapies. The Association also continues to move proactively to speed therapy development combining efficient new drug discovery approaches with priorities set for existing drug candidates to accelerate clinical testing of compounds with promise for the disease. In FYE 2013 more than $6.6 million was awarded by The Association through TREAT ALS in the form of grants, drug discovery contracts and clinical and research studies. Major funding was provided for the development of remote treatment strategies to aid home care of people with ALS, preclinical assessment of potential therapeutic compounds, biomarker development studies, and clinical pilot studies of new treatment strategies for ALS, in partnership with the Northeast ALS Consortium (NEALS) Clinical Trial Network. In March 2012, The Association brought together more than 120 researchers, drug developers, government officials, and other interested parties to brainstorm on ways to accelerate drug discovery for ALS treatment.

MAKING THE CASE: SUCCESSFUL ADVOCACY ON CAPITOL HILL

Every year in the nation’s capital, The ALS Association hosts the National ALS Advocacy Day and Public Policy Conference—a three-day event in which people touched by Lou Gehrig’s Disease from all walks of life and from nearly every state in the country gather to make their voices heard. At the 2012 conference held May 13 to 15, more than 900 attendees told the ALS story—their personal experiences and those of their loved ones—and urged legislators to support the needs of the ALS community.

One of the main goals was to urge Congress to step up the fight for a treatment and cure, and on that score the conference was a resounding success. Advocates held more than 400 meetings with members of Congress, and their compelling stories moved legislators to act swiftly. In addition to triggering the 17 percent increase in the ALS Research Program passed by the House of Representatives, the meetings led to a more than doubling of the number of co-sponsors of the Modernizing Our Drug and Diagnostics Evaluation and Regulatory Network (MODDERN) Cures Act, legislation that would provide incentives to encourage the development of new treatments for diseases with unmet medical needs, including ALS. With bipartisan support, that legislation was introduced by Rep. Leonard Lance (R-NJ).

Public Policy Conference Offers Many Highlights. The conference was memorable in many ways. Dr. Kevin Horton, who leads the National ALS Registry at the Centers for Disease Control and Prevention, unveiled exciting new features of the registry, including modules that will collect additional information about the disease (such as information on head trauma) to help researchers find clues to the cause of ALS. Dr. Horton also announced the launching of a new tool that notifies people enrolled in the registry about clinical trials for which they may be eligible to participate. The conference featured the first-ever “familial ALS Summit” (fALS), where participants learned about exciting research into fALS and were able to share their personal experiences on issues unique to familial cases. At other sessions, renowned ALS researchers and representatives of the pharmaceutical and biotech industries discussed the latest advances in ALS research and the promising clinical trials underway.
National ALS Registry Brings Many Benefits. FYE 2013 was also notable for the continued support garnered for the National ALS Registry, which went live on October 19, 2010, and has the potential to become the single largest ALS research project ever created. The ALS Association led the successful fight to establish the registry and secure federal funding to design, build and implement it at the Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry. The registry’s aim is to identify ALS cases throughout the United States—every person in the country living with Lou Gehrig’s Disease can self-enroll—and, more importantly, to collect critical information about the disease that will improve care, reveal insights into its causes, and point researchers toward potential treatment and prevention strategies.

In FYE 2013, The Association worked with Reps. Eliot Engel (D-NY) and Peter King (R-NY) to circulate a “Dear Colleague” letter among members of Congress to ensure continued funding for the registry. More than 45 members signed the letter, which was delivered to the House Appropriations Committee. In the Senate, the Appropriations Committee voted to provide an additional $6 million to continue the registry. The legislation ultimately passed, bringing total registry funding to more than $30 million.

Research Funding Increases. Meanwhile, the increase for the ALS Research Program at the Department of Defense to $7.5 million brings the total funding for the program to $40 million, all of which is explicitly focused on finding treatments for ALS. The vote came after The Association worked with Reps. Elton Gallegly (R-CA) and Chellie Pingree (D-ME) to circulate a “Dear Colleague” letter in the House, which was signed by 55 members of Congress.

FDA Policies Aim to Accelerate Drug Approval Process. The Association also worked with the U.S. Food and Drug Administration in FYE 2013 to enact two important policies aiming to expedite the development and approval of ALS treatments. The Food and Drug Administration Safety and Innovation Act, signed into law on July 9, 2012, and the Prescription Drug User Fee Act, renewed for the fifth time in 2012, include important provisions that, among other things, strengthen the fast-track and accelerated approval processes to speed access to new treatments; require the FDA to partner more closely with patient organizations representing those with rare diseases; and provide additional flexibility for the FDA to approve new treatments more quickly through the use of biomarkers and other surrogate endpoints.

ENSURING STATE-OF-THE-ART CARE AND SUPPORT

While leaving no stone unturned in the pursuit of better treatments and a cure for Lou Gehrig’s Disease, The ALS Association is equally focused on ensuring excellent care and support for the people who are currently living with ALS, as well as for the family members who are going through the ordeal with them. The Association’s nationwide network of chapters and other partners provide local patient and family support in communities across the country. Each chapter is a grass-roots organization that carries out The Association’s mission and strategic goals at the community level.

With support from the national office, chapters provide a wide range of services for people living with ALS, their caregivers, families and friends, along with professional health care providers throughout the service area. This includes patient education programs, support groups and referral services, as well as equipment loan programs, augmentative communication device programs, and referrals to ALS clinics and physicians. In addition, The ALS Association’s Certified Center program defines, establishes and supports a national standard of care in the management of ALS, including multidisciplinary, state-of-the-art care and services in a supportive atmosphere that emphasizes hope and quality of life. The Association supports 34 Certified Centers of Excellence as well as 42 non-certified clinics providing services that follow nationally established “best practice” standards of care.

As part of The Association’s continued effort to ensure the most effective care for ALS patients, a cost study was initiated using data collected through 18 of The Association’s Certified Centers. The goal: to identify specific costs associated with providing care through a clinical center of excellence. An additional
case study of one family’s financial journey was completed on a retrospective basis. Results from each of these studies were presented at the ALS/MND International Symposium in December 2012.

**A Wide-Ranging Educational Curriculum.** Recognizing the importance of education for providers, staff, people living with the disease, families and caregivers, The Association has developed an education curriculum that includes meetings for medical directors, a national clinical conference, regional meetings, assistive technology and professional topic webinars, research updates, sessions at the National ALS Advocacy Day and Public Policy Conference, and a library of more than 50 published documents. The national office handles more than 400 information requests and referral programs per month.

Meanwhile, The Association continues to work with chapters and providers to identify opportunities and models of service delivery that will expand access to The Association's services and programs, while achieving consistency in our portfolio across the country. Recognizing the value of collaboration, The Association also continues to reach out to other organizations in an effort to increase effectiveness and efficiencies.

**SPREADING THE WORD AND ENLISTING NEW MEMBERS TO THE CAUSE**

For the thousands who are affected by Lou Gehrig's Disease now and in the future, having a reliable information source as well as open lines of communication with both experts and others experiencing the same struggles is vitally important. Moreover, while people with ALS and their loved ones know all too well about the havoc wreaked by ALS, tens of millions of Americans who haven’t been personally affected must be made aware of the urgency to overcome this terrible disease.

**Website Enhances Visibility.** The Association works on all of these fronts to improve awareness of Lou Gehrig's Disease, starting with our website (www.alsa.org). In FYE 2013, many improvements were made to the site to keep it fresh and enhance the visitor experience. These included greater visibility for stories published by The Association, links to general news stories about ALS, a reorganized front-page navigation, and an embedded Twitter feed. The reorganization also provides a more direct path for users to take action, with a one-click “donate now” button highlighted, as well as larger links reading: “Advocate” and “Help Fight ALS.” These improvements have contributed to a significant increase in traffic on the page, with the average monthly unique-visitor rate growing by 100,000 over the previous year. Overall, traffic to the site is well above benchmarks for disease and health charities and has recently begun to exceed the benchmark for the largest nonprofits.

**Social Media Outlets Help to Increase Interaction.** Social media also continues to play an increasingly important role as a vehicle for sharing information and interacting with families fighting ALS, as well as with the general public. The Association utilizes several social media channels, including Facebook, Twitter, LinkedIn, Google+ and Pinterest, sharing information about its research and care services programs, public policy endeavors, and awareness activities. In FYE 2013, for the first time The Association live-streamed Advocacy Day conference sessions on our Facebook page for conference non-attendees. For the year, Facebook “likes” increased by more than 25 percent, while Twitter followers grew by 40 percent. In an effort to help people with ALS enroll in the National ALS Registry, The Association engaged in a number of public awareness activities, including a national awareness campaign with Minor League Baseball and a nationwide ALS Registry public service announcement featuring baseball great Tommy John.

**Outreach to Traditional Media Keeps ALS in Public Eye.** Enhancing awareness is also accomplished through traditional media. Partly due to a more robust media outreach effort and an increase in the number and frequency of ALS research study publications, The Association experienced a 39 percent increase in media mentions in FYE 2013 compared with the previous year. The Association held its annual Veterans Day letter-to-the-editor campaign, and staff participated in interviews for newspaper articles and talk-radio programs. Particularly notable was a television public service announcement (PSA) produced by The Association with TV and Broadway star Jason Alexander and Steve Posso, who has lived with ALS since 2007. The PSA debuted in January 2012 and soon was appearing on network, regional and cable TV stations nationwide, airing nearly 18,000 times on more than 140 stations to a viewing audience of 408 million for the year, as well as being shown in movie theaters across the country. This effort amounted to more than $6 million in donated, in-kind advertising revenue.
Walk to Defeat ALS® Marches On. Finally, there was the Walk to Defeat ALS, a nationwide campaign to bring hope to people with the disease while raising money for a cure through high-profile events. FYE 2013 represented a new milestone for the program, with 170 walks and approximately 175,000 walkers raising $21.7 million—a six percent increase over the previous year. Since 2000, the Walk to Defeat ALS has contributed more than $159 million toward the fight to bring an end to the disease.

FIGHTING FOR THOSE WHO CAN’T

Lou Gehrig’s Disease robs individuals of their physical capabilities. It can be extremely trying not only for people with the disease, but also for family members who must stand by as their loved ones deteriorate, powerless to prevent the decline. But through the efforts of The ALS Association, these individuals will never feel alone. Indeed, they are not alone. They are joined by the legions of community members all over the country, enlisted to the cause and walking in solidarity with those who can no longer do so. The Association is fighting for all of these individuals. And as we continue our march toward a world without ALS, our pace is accelerating.
<table>
<thead>
<tr>
<th>CONTENTS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>INDEPENDENT AUDITORS’ REPORT</td>
<td>11</td>
</tr>
<tr>
<td>STATEMENT OF FINANCIAL POSITION</td>
<td>12</td>
</tr>
<tr>
<td>STATEMENT OF ACTIVITIES</td>
<td>13</td>
</tr>
<tr>
<td>STATEMENT OF FUNCTIONAL EXPENSES</td>
<td>14</td>
</tr>
<tr>
<td>STATEMENT OF CASH FLOWS</td>
<td>15</td>
</tr>
<tr>
<td>NOTES TO THE FINANCIAL STATEMENTS</td>
<td>16-20</td>
</tr>
</tbody>
</table>
Report on the Financial Statements
We have audited the accompanying financial statements of The Amyotrophic Lateral Sclerosis Association (The “Association”) which comprise the statement of financial position as of January 31, 2013, and the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

Management’s Responsibility for the Financial Statements
Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ Responsibility
Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of The Association at January 31, 2013, and the changes in its net assets and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

Report on Summarized Comparative Information
We have previously audited The Amyotrophic Lateral Sclerosis Association’s 2012 financial statements, and our report dated May 17, 2012, expressed an unmodified opinion on those audited financial statements. In our opinion, the summarized comparative information presented herein as of and for the year ended January 31, 2012, is consistent, in all material respects, with the audited financial statements from which it has been derived.

Other Reporting Required by Government Auditing Standards
In accordance with Government Auditing Standards, we have also issued our report dated June 18, 2013, on our consideration of The Amyotrophic Lateral Sclerosis Association’s internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with Government Auditing Standards in considering The Amyotrophic Lateral Sclerosis Association’s internal control over financial reporting and compliance.

INDEPENDENT AUDITORS’ REPORT

The Board of Trustees
The Amyotrophic Lateral Sclerosis Association

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of The Association at January 31, 2013, and the changes in its net assets and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

Report on Summarized Comparative Information
We have previously audited The Amyotrophic Lateral Sclerosis Association’s 2012 financial statements, and our report dated May 17, 2012, expressed an unmodified opinion on those audited financial statements. In our opinion, the summarized comparative information presented herein as of and for the year ended January 31, 2012, is consistent, in all material respects, with the audited financial statements from which it has been derived.

Other Reporting Required by Government Auditing Standards
In accordance with Government Auditing Standards, we have also issued our report dated June 18, 2013, on our consideration of The Amyotrophic Lateral Sclerosis Association’s internal control over financial reporting and compliance and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with Government Auditing Standards in considering The Amyotrophic Lateral Sclerosis Association’s internal control over financial reporting and compliance.

Long Beach, California
June 18, 2013
## STATEMENT OF FINANCIAL POSITION
FOR THE FISCAL YEAR ENDED JANUARY 31, 2013, WITH COMPARATIVE TOTALS FOR 2012

<table>
<thead>
<tr>
<th>JANUARY 31, 2013</th>
<th>2012</th>
</tr>
</thead>
</table>

### ASSETS

<table>
<thead>
<tr>
<th>ASSET</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$7,302,712</td>
<td>$6,834,970</td>
</tr>
<tr>
<td>Investments in marketable securities</td>
<td>$7,314,287</td>
<td>$6,724,420</td>
</tr>
<tr>
<td>Receivables:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bequests, net</td>
<td>$333,604</td>
<td>$731,231</td>
</tr>
<tr>
<td>Chapters, net</td>
<td>$2,695,876</td>
<td>$3,724,841</td>
</tr>
<tr>
<td>Pledges, net</td>
<td>$696,219</td>
<td>$321,402</td>
</tr>
<tr>
<td>Other</td>
<td>$38,105</td>
<td>$174,318</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>$230,418</td>
<td>$305,027</td>
</tr>
<tr>
<td>Beneficial interest in perpetual trusts</td>
<td>$970,275</td>
<td>$939,667</td>
</tr>
<tr>
<td>Contributions receivable from remainder trusts</td>
<td>$207,483</td>
<td>$291,389</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>$222,142</td>
<td>$165,883</td>
</tr>
<tr>
<td>Other assets</td>
<td>$48,848</td>
<td>$43,191</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>$20,059,969</td>
<td>$20,256,339</td>
</tr>
</tbody>
</table>

### LIABILITIES AND NET ASSETS

<table>
<thead>
<tr>
<th>LIABILITIES</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Grants payable</td>
<td>$180,334</td>
<td>$453,556</td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$1,345,713</td>
<td>$1,167,003</td>
</tr>
<tr>
<td>Annuity payment liability</td>
<td>$788,970</td>
<td>$754,538</td>
</tr>
<tr>
<td>Deferred rent</td>
<td>$242,758</td>
<td>$385,859</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td>$2,557,775</td>
<td>$2,760,956</td>
</tr>
</tbody>
</table>

**COMMITMENTS (Note 6)**

<table>
<thead>
<tr>
<th><strong>NET ASSETS</strong></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>$8,317,870</td>
<td>$8,106,576</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>$8,260,444</td>
<td>$8,492,325</td>
</tr>
<tr>
<td>Permanently restricted</td>
<td>$923,880</td>
<td>$896,482</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td>$17,502,194</td>
<td>$17,495,383</td>
</tr>
</tbody>
</table>

**TOTAL LIABILITIES AND NET ASSETS**

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>$20,059,969</strong></td>
<td><strong>$20,256,339</strong></td>
<td></td>
</tr>
</tbody>
</table>
## STATEMENT OF ACTIVITIES
FOR THE FISCAL YEAR ENDED JANUARY 31, 2013, WITH COMPARATIVE TOTALS

<table>
<thead>
<tr>
<th></th>
<th>UNRESTRICTED</th>
<th>TEMPORARILY RESTRICTED</th>
<th>PERMANENTLY RESTRICTED</th>
<th>TOTAL 2013</th>
<th>TOTAL 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SUPPORT AND REVENUE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions</td>
<td>$ 5,960,075</td>
<td>$ 2,377,873</td>
<td></td>
<td>$ 8,337,948</td>
<td>$ 7,177,133</td>
</tr>
<tr>
<td>Bequests</td>
<td>2,108,599</td>
<td>486,027</td>
<td></td>
<td>2,594,626</td>
<td>3,222,798</td>
</tr>
<tr>
<td>Chapters</td>
<td>4,470,652</td>
<td>3,256,773</td>
<td></td>
<td>7,727,425</td>
<td>7,572,676</td>
</tr>
<tr>
<td>In-kind public service announcements</td>
<td>6,030,011</td>
<td></td>
<td>6,030,011</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Events, net of expenses</td>
<td>317,220</td>
<td></td>
<td></td>
<td>725,631</td>
<td>99,175</td>
</tr>
<tr>
<td>Federated campaigns</td>
<td>327,865</td>
<td></td>
<td></td>
<td>334,174</td>
<td>54,211</td>
</tr>
<tr>
<td>Investment income</td>
<td>298,915</td>
<td>73,633</td>
<td></td>
<td>372,548</td>
<td>99,175</td>
</tr>
<tr>
<td>Other income</td>
<td>87,411</td>
<td></td>
<td></td>
<td>87,411</td>
<td>54,211</td>
</tr>
<tr>
<td>Gain on beneficial interest in perpetual trusts</td>
<td></td>
<td></td>
<td>$ 27,398</td>
<td>27,398</td>
<td>29,180</td>
</tr>
<tr>
<td>Change in value of split-interest agreements</td>
<td>(77,940)</td>
<td></td>
<td></td>
<td>(77,940)</td>
<td>(172,401)</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>6,348,247</td>
<td>(6,348,247)</td>
<td></td>
<td>25,744,512</td>
<td>19,042,577</td>
</tr>
<tr>
<td><strong>Total support and revenue</strong></td>
<td>25,948,995</td>
<td>(231,881)</td>
<td></td>
<td>25,744,512</td>
<td>19,042,577</td>
</tr>
<tr>
<td><strong>EXPENSES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research grants</td>
<td>6,616,367</td>
<td></td>
<td></td>
<td>6,616,367</td>
<td>3,904,240</td>
</tr>
<tr>
<td>Patient and community services</td>
<td>5,046,087</td>
<td></td>
<td></td>
<td>5,046,087</td>
<td>4,629,111</td>
</tr>
<tr>
<td>Public and professional education</td>
<td>8,878,559</td>
<td></td>
<td></td>
<td>8,878,559</td>
<td>1,859,100</td>
</tr>
<tr>
<td>Fundraising</td>
<td>3,000,946</td>
<td></td>
<td></td>
<td>3,000,946</td>
<td>3,269,624</td>
</tr>
<tr>
<td>Administration</td>
<td>2,195,742</td>
<td></td>
<td></td>
<td>2,195,742</td>
<td>1,773,152</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td>25,737,701</td>
<td></td>
<td></td>
<td>25,737,701</td>
<td>15,435,227</td>
</tr>
<tr>
<td><strong>CHANGE IN NET ASSETS</strong></td>
<td>211,294</td>
<td>(231,881)</td>
<td>27,398</td>
<td>6,811</td>
<td>3,607,350</td>
</tr>
<tr>
<td><strong>NET ASSETS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beginning of year</td>
<td>8,106,576</td>
<td>8,492,325</td>
<td>896,482</td>
<td>17,495,383</td>
<td>13,888,033</td>
</tr>
<tr>
<td><strong>NET ASSETS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>End of year</td>
<td>$8,317,870</td>
<td>8,260,444</td>
<td>$923,880</td>
<td>$17,502,194</td>
<td>$17,495,383</td>
</tr>
</tbody>
</table>

See Independent Auditors' Report. The accompanying notes are an integral part of these financial statements.
STATEMENT OF FUNCTIONAL EXPENSES
JANUARY 31, 2013, WITH COMPARATIVE TOTALS FOR 2012

<table>
<thead>
<tr>
<th>EXPENSES</th>
<th>PROGRAM ACTIVITIES</th>
<th>SUPPORTING ACTIVITIES</th>
<th>TOTAL EXPENSES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RESEARCH GRANTS</td>
<td>PATIENT AND COMMUNITY SERVICES</td>
<td>PUBLIC AND PROFESSIONAL EDUCATION</td>
</tr>
<tr>
<td>Grant awards</td>
<td>$5,993,945</td>
<td>$766,429</td>
<td>$20,000</td>
</tr>
<tr>
<td>Chapter support</td>
<td>1,005,327</td>
<td>1,005,327</td>
<td></td>
</tr>
<tr>
<td>Salaries and related expenses</td>
<td>33,524</td>
<td>2,015,958</td>
<td>1,019,820</td>
</tr>
<tr>
<td>Printing, publications and</td>
<td>7</td>
<td>143,898</td>
<td>197,361</td>
</tr>
<tr>
<td>public service announcements</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In-kind public service announcements</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Professional fees and</td>
<td>273,280</td>
<td>495,597</td>
<td>899,297</td>
</tr>
<tr>
<td>contract services</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postage and shipping</td>
<td>5</td>
<td>15,618</td>
<td>24,954</td>
</tr>
<tr>
<td>Rent and occupancy</td>
<td>143,943</td>
<td>93,228</td>
<td>237,171</td>
</tr>
<tr>
<td>Travel and conferences</td>
<td>305,974</td>
<td>327,297</td>
<td>435,972</td>
</tr>
<tr>
<td>Telecommunications</td>
<td>9,191</td>
<td>50,339</td>
<td>41,281</td>
</tr>
<tr>
<td>Office supplies</td>
<td>21</td>
<td>12,716</td>
<td>59,022</td>
</tr>
<tr>
<td>Dues and subscriptions</td>
<td>420</td>
<td>17,895</td>
<td>42,831</td>
</tr>
<tr>
<td>Bad-debt expense (recoveries)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation</td>
<td>38,799</td>
<td>8,195</td>
<td>46,994</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>12,271</td>
<td>6,587</td>
<td>18,858</td>
</tr>
</tbody>
</table>

| 2013 TOTALS                                  | $6,616,367     | $5,046,087              | $8,878,559          | $20,541,013 | $3,000,946 | $2,195,742 | $5,196,688 | 25,737,701 |
| 2012 TOTALS                                  | $3,904,240     | $4,629,111              | $1,859,100          | $10,392,451 | $3,269,624 | $1,773,152 | $5,042,776 | 15,435,227 |

PERCENTAGE OF TOTAL EXPENSES

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grant awards</td>
<td>25.7%</td>
<td>25.3%</td>
</tr>
<tr>
<td>Chapter support</td>
<td>19.6%</td>
<td>30.0%</td>
</tr>
<tr>
<td>Salaries and related expenses</td>
<td>34.5%</td>
<td>12.0%</td>
</tr>
<tr>
<td>Professional fees and contract services</td>
<td>79.8%</td>
<td>67.3%</td>
</tr>
<tr>
<td>Postage and shipping</td>
<td>11.7%</td>
<td>21.2%</td>
</tr>
<tr>
<td>Rent and occupancy</td>
<td>8.5%</td>
<td>11.5%</td>
</tr>
<tr>
<td>Travel and conferences</td>
<td>20.2%</td>
<td>32.7%</td>
</tr>
</tbody>
</table>

See Independent Auditors’ Report. The accompanying notes are an integral part of these financial statements.
STATEMENT OF CASH FLOWS  
JANUARY 31, 2013, WITH COMPARATIVE TOTALS FOR 2012

| CASH FLOWS FROM OPERATING ACTIVITIES | FROM YEAR ENDED JANUARY 31, |
|                                      | 2013 | 2012 |
| Change in net assets                | $6,811 | $3,607,350 |

Adjustments to reconcile change in net assets to net cash flows from operating activities:

- Depreciation                      | 76,007 | 153,243 |
- Realized/unrealized (gain) loss on investments | (209,576) | 20,792 |
- Disposal of equipment              | 4,181  |       |
- Noncash contributions to investments | (63,879) | (33,158) |
- Change in beneficial interest in perpetual trusts | (30,608) | (311,998) |
- Change in value of charitable remainder trusts | 83,906 | 12,404 |
- Changes in operating assets and liabilities:
  - Receivables:
    - Bequests net                     | 397,627 | 590,524 |
    - Chapters, net                    | 1,028,965 | (910,388) |
    - Pledges, net                     | (374,817) | 177,143 |
    - Other                           | 136,213 | (150,155) |
  - Prepaid expenses                  | 74,609  | (146,381) |
  - Other assets                      | (5,657)  |       |
  - Grants payable                    | (273,222) | (892,329) |
  - Accounts payable and accrued expenses | 178,710 | (580,640) |
  - Annuity payment liability         | 34,432  | 142,607 |
  - Deferred rent                     | (143,101) | 236,956 |
  - Net Cash Provided by Operating Activities | 920,601 | 1,915,970 |

CASH FLOWS FROM INVESTING ACTIVITIES

- Proceeds from sold and matured investments | 1,534,182 | 2,193,407 |
- Purchases of investments                  | (1,850,594) | (6,574,785) |
- Purchases of property and equipment       | (136,447) | (40,098) |
  - Net Cash Used In Investing Activities   | (452,859) | (4,421,476) |

NET CHANGE IN CASH AND CASH EQUIVALENTS

|                              | FROM YEAR ENDED JANUARY 31, |
|                              | 2013 | 2012 |
|                              | 467,742 | (2,505,506) |

CASH AND CASH EQUIVALENTS–Beginning of year | 6,834,970 | 9,340,476 |

CASH AND CASH EQUIVALENTS–End of year | $7,302,712 | $6,834,970 |

CONSOLIDATED FINANCIAL SUMMARY, NATIONAL OFFICE AND CHAPTERS
FOR THE YEAR ENDED JANUARY 31, 2013

|                              | $64,661,521 |
|                              | TOTAL COMBINED REVENUE |

|                              | $61,332,720 |
| TOTAL COMBINED EXPENSES |

|                              | $6,616,367 |
| Research                     |

|                              | 40,164,177 |
| Other program activities     |

|                              | 9,137,186 |
| Fundraising                  |

|                              | $5,414,990 |
| General & administration     |

Total expenses | $61,332,720 |

Change in net assets: | $3,328,800 |

The consolidated summary has not been audited or reviewed by the auditors and is not part of their financial reports.

See Independent Auditors’ Report. The accompanying notes are an integral part of these financial statements.
THE ASSOCIATION

The Amyotrophic Lateral Sclerosis Association (The Association) was organized in 1985 through the merger of its predecessors, The Amyotrophic Lateral Sclerosis Society of America and The National ALS Foundation, Inc. The Association’s principal purpose is to fund research directed at finding the cause and cure for the disease amyotrophic lateral sclerosis (ALS), commonly known as “Lou Gehrig’s Disease,” and to provide educational and other services to patients and their families, health care professionals, legislators, and local communities, principally through the dissemination of informative literature and presentation of public awareness and advocacy programs and scientific symposiums and by accrediting, with local chapter support, activities of patient care clinics known as ALS Association Centers.

The Association is a not-for-profit, voluntary health organization, exempt, together with its affiliated chapters, from federal income taxes under Section 501(c)(3) of the Internal Revenue Code (the Code). The ALS Association and its chapters are classified collectively as a publicly supported charitable organization under Section 509(a)(1) and qualify for the maximum charitable contribution deduction by donors under Section 170(b)(1)(A)(vi) of the Code.

These financial statements do not include the accounts of affiliated chapters since, subject to their agreements with The Association, they are independently controlled by their own governing boards.

BASIS OF PRESENTATION

The accompanying financial statements include a statement of financial position that presents the amounts for each of three classes of net assets—unrestricted net assets, temporarily restricted net assets, and permanently restricted net assets—based on the existence or absence of donor-imposed restrictions, a statement of activities that reflects the changes in those categories of net assets, and a statement of functional expenses that associates expenses with service efforts.

Unrestricted net assets include those net assets that may be used by The Association for any of its programs or administrative support. Temporarily restricted net assets include those net assets whose use by The Association has been limited by donors to specified purposes or time restrictions. Permanently restricted net assets include those net assets that must be maintained in perpetuity.

PRIOR-PERIOD INFORMATION

The financial statements include certain prior-year summarized comparative information in total but not by net asset class. Such information does not include sufficient detail to constitute a presentation in conformity with accounting principles generally accepted in the United States of America. Accordingly, such information should be read in conjunction with The Association’s financial statements for the year ended January 31, 2012, from which the summarized information was derived.

USE OF ESTIMATES

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

CASH AND CASH EQUIVALENTS

Cash equivalents are defined as money market funds and other highly liquid investments with original maturities of three months or less at the date they are purchased.

INVESTMENTS IN MARKetable SECURITIES

Investments are initially recorded at cost if purchased, or at fair value at the date of donation if contributed. Subsequent to acquisition, investments are reported at their fair value. Investment income and realized and unrealized gains and losses are recognized as unrestricted net assets unless their use is temporarily or permanently restricted by donors to a specified purpose or future period. The fair value of investments in securities traded on a national securities exchange are valued at the closing price on the last business day of the fiscal year, whereas securities traded on the over-the-counter market are valued at the last reported bid price.
NOTE 1—Description of Operations and Summary of Accounting Policies—CONT.

FINANCIAL RISK
The Association maintains cash in bank deposit accounts which, at times, may exceed federally insured limits. The Association places its cash with high quality financial institutions and has not experienced any losses in such accounts.

The Association’s investments are exposed to various risks, such as market and credit risks. Due to the level of risk associated with such investments and the level of uncertainty related to changes in the value of such investments, it is at least reasonably possible that changes in risks in the near term could materially affect investment balances and the amounts reported in the financial statements.

CONTRIBUTIONS AND BEQUESTS
Contributions, including endowment gifts and pledges, are recognized as support in the period received or pledged. Unconditional promises to give that are expected to be collected within one year are recorded at their net realizable value. Unconditional promises to give that are expected to be collected in future years are recorded at the present value of their estimated future cash flows. Amortization of the discount to present value is included in contribution revenue. Conditional promises to give are not included as support until the conditions are substantially met.

Bequests are recognized at the time The Association’s right to them is established by a court and the proceeds are subject to reasonable estimation.

Donations and bequests received with donor stipulations as to their intended use are reported in the statement of activities as restricted support. Temporarily restricted net assets are reclassified as unrestricted net assets when restrictions are met.

Contributed services are reported at fair value in the financial statements for voluntary donations of services when those services (1) create or enhance nonfinancial assets or (2) require specialized skills provided by individuals possessing those skills and are services which would be typically purchased if not provided by donation. The Association receives a substantial number of volunteer hours donated by individuals in program services and fundraising campaigns which are not recorded in the financial statements. Donated materials are recorded at their fair value at the date of the gift. If donors stipulate how long donated assets must be used, the contributions are recorded as restricted support. In the absence of such stipulations, contributions of goods are recorded as unrestricted support.

Beneficial interests in perpetual trusts are recognized as revenue when The Association is notified of the trust’s existence in accordance with the terms and provisions of the trust. The fair value of the contribution is estimated using the fair value of the assets contributed to the trust, unless facts and circumstances indicate that the fair value of the beneficial interest differs from the fair value of the assets contributed to the trust. The contribution is classified as temporarily or permanently restricted support, depending on the nature of donor restriction, and annual distributions from the trust are reported as investment income that increases unrestricted net assets. At each reporting date, the beneficial interest is remeasured at fair value using the same valuation technique that was used to measure the asset initially and the change in fair value is recognized as temporarily or permanently restricted gains or losses.

The Association is the beneficiary of two charitable remainder trusts for which The Association is not the trustee. The Association recognizes the present value of the estimated future benefits to be received when the trust assets are distributed as temporarily restricted contribution revenue and as a receivable. Adjustments to the receivable to reflect amortization of the discount and revaluation of the present value of the estimated future payments to the lifetime beneficiary are recognized in the statement of activities as change in value of split-interest agreements.

IN-KIND CONTRIBUTIONS
The Association produces and distributes public-service television announcements that focus attention on education and awareness. These public service announcements are distributed to media stations nationwide and run free of charge. The Association has contracted with an independent outside agency to track the date and time that each public service announcement runs, and the value of the announcements is based on the date, time and market. For the year ended January 31, 2013, The Association recorded $6,030,011 of contributed public service announcements.

CHAPTER SUPPORT
The Association has a revenue-sharing practice with affiliated chapters. Chapter support is recognized as support revenue when earned by the affiliated chapter based on the current revenue-sharing plan.

From time to time, The Association may provide loans for working capital needs to affiliated chapters. Generally, repayment of the loan begins one year from the date of the last loan installment. In the current year, The Association entered into three zero-interest twenty-year loans with three affiliated chapters. These loans to affiliated chapters are discounted at three percent based on the long-term Applicable Federal Rate (AFR), which is what the IRS would use to determine the unstated interest rate.
PROPERTY AND EQUIPMENT
Expenditures for property and equipment are capitalized at cost or, for donated assets, fair value at the time of donation. Depreciation and amortization is provided on a straight-line basis over the estimated useful lives of the related assets, ranging from three to five years.

RESEARCH GRANT EXPENSE
Conditional research grants (see Note 6) are expensed by The Association as the researchers substantially meet the terms and conditions of the grant during the grant period. Unconditional research grants are expensed when made.

FUNCTIONAL EXPENSES
The costs of providing various programs and activities of The Association have been summarized on a functional basis in the statements of activities and functional expenses. The majority of expenses are directly identified with a program, activity or supporting service and allocated accordingly. Expenses not directly identified are allocated among programs, activities and supporting services based on the judgment of management.

ALLOCATION OF JOINT COSTS
The Association incurred joint costs for informational mailings that included fundraising appeals. The Association is permitted through accounting guidance to allocate to its programs a portion of its costs associated with its fundraising efforts. Costs are allocated between program and fundraising based on the percentage of words used for each purpose in a mailing. For the year ended January 31, 2013, joint costs totaled $767,012 and $238,468 for fundraising and program services, respectively.

INCOME TAXES
The Association is exempt from federal income taxes under Internal Revenue Code Section 501(c)(3) and state taxes related to revenue received in connection with exempt programs. The Association recognizes the financial statement benefit of tax positions, such as its filing status as tax-exempt, only after determining that the relevant tax authority would more likely than not sustain the position following an audit. The Association is subject to potential income tax audits on open tax years by any taxing jurisdiction in which it operates. The statute of limitations for federal purposes is three years and for state purposes is generally three to four years.

SUBSEQUENT EVENTS
The Association has evaluated subsequent events and transactions for potential recognition or disclosure through June 18, 2013, the date financial statements were available to be issued.

NOTE 2–Investments in Marketable Securities—CONT.

Investments in marketable securities consist of the following:

<table>
<thead>
<tr>
<th>JANUARY 31,</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutual funds</td>
<td>$3,267,077</td>
<td>$2,955,154</td>
</tr>
<tr>
<td>Equity securities</td>
<td>$1,930,040</td>
<td>$1,697,326</td>
</tr>
<tr>
<td>Corporate bonds</td>
<td>$1,113,379</td>
<td>$1,070,521</td>
</tr>
<tr>
<td>Government agency obligations</td>
<td>$675,348</td>
<td>$619,883</td>
</tr>
<tr>
<td>Government backed mortgage securities</td>
<td>$134,734</td>
<td>$175,362</td>
</tr>
<tr>
<td>Corporate mortgage securities</td>
<td>$193,709</td>
<td>$172,013</td>
</tr>
<tr>
<td>Others</td>
<td>$34,161</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$7,314,287</strong></td>
<td><strong>$6,724,420</strong></td>
</tr>
</tbody>
</table>

NOTE 3–Chapter Receivables
Receivables from Chapters consist of the following:

<table>
<thead>
<tr>
<th>JANUARY 31,</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue sharing</td>
<td>$1,864,382</td>
<td>$3,308,665</td>
</tr>
<tr>
<td>Reserve for doubtful collection</td>
<td>(123,436)</td>
<td>(365,435)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$1,740,946</strong></td>
<td><strong>$2,943,230</strong></td>
</tr>
</tbody>
</table>

Revenue sharing
Reserve for doubtful collection

For the year ended January 31, 2013, $162,972 in interest income was earned and $209,576 was realized for a realized/unrealized gain (loss) of $372,548. For the year ended January 31, 2012, $119,967 in interest income was earned and $(20,792) was realized for a realized/unrealized gain (loss) of $99,175.
**NOTE 4–Pledges Receivables**

The Association anticipates collection of outstanding pledges receivable as follows:

<table>
<thead>
<tr>
<th></th>
<th>JANUARY 31,</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2013</td>
<td>2012</td>
<td></td>
</tr>
<tr>
<td>Gross amounts due in:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Less than one year</td>
<td>$549,363</td>
<td>$273,888</td>
<td></td>
</tr>
<tr>
<td>One to five years</td>
<td>238,025</td>
<td>203,700</td>
<td></td>
</tr>
<tr>
<td>More than five years</td>
<td>15,000</td>
<td>15,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>802,388</td>
<td>492,588</td>
<td></td>
</tr>
<tr>
<td>Less discount to present value</td>
<td>(19,948)</td>
<td>(24,011)</td>
<td></td>
</tr>
<tr>
<td>Less reserve for uncollectible pledges</td>
<td>(86,221)</td>
<td>(147,175)</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>$696,219</td>
<td>$321,402</td>
<td></td>
</tr>
</tbody>
</table>

Amounts presented above have been discounted to present value using rates ranging from 1.54% to 4.75%.

**NOTE 5–Property and Equipment**

Property and equipment consists of the following:

<table>
<thead>
<tr>
<th></th>
<th>JANUARY 31,</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2013</td>
<td>2012</td>
<td></td>
</tr>
<tr>
<td>Furniture and equipment</td>
<td>$769,425</td>
<td>$746,514</td>
<td></td>
</tr>
<tr>
<td>Software</td>
<td>314,806</td>
<td>314,806</td>
<td></td>
</tr>
<tr>
<td>Leasehold improvements</td>
<td>185,327</td>
<td>185,327</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1,269,558</td>
<td>1,246,647</td>
<td></td>
</tr>
<tr>
<td>Less accumulated depreciation and amortization</td>
<td>(1,148,278)</td>
<td>(1,080,764)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>121,280</td>
<td>165,883</td>
<td></td>
</tr>
<tr>
<td>Construction in process</td>
<td>100,862</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$222,142</td>
<td>$165,883</td>
<td></td>
</tr>
</tbody>
</table>

**NOTE 6–Commitments**

**RESEARCH GRANTS**

The Association enters into conditional commitments semiannually to award scientific research grants. Research grants are awarded after review by The Association’s Scientific Review Committee and approval by the Board of Trustees. Subject to an annual review and reapproval process, these grants generally cover a period of one to three years.

Subject to the grantees’ meeting the applicable terms and conditions timely, conditional grants awarded to date will become payable as follows:

<table>
<thead>
<tr>
<th>YEAR ENDING</th>
<th>JANUARY 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>$4,763,812</td>
</tr>
<tr>
<td>2015</td>
<td>1,482,229</td>
</tr>
<tr>
<td>2016</td>
<td>464,149</td>
</tr>
<tr>
<td>Total</td>
<td>$6,710,190</td>
</tr>
</tbody>
</table>

Rent expense under office and equipment leases amounted to $524,562 and $784,787 for the years ended January 31, 2013 and 2012, respectively.

In January 2013, The Association entered into a sublease agreement with a Chapter which terminates November 2015. The Association expects to receive rental proceeds of approximately $60,000 in each of the next three years under this agreement.

**PURCHASE COMMITMENTS**

The Association has entered into a purchase agreement with a hotel for guest rooms relating to its annual conferences. Purchases under these agreements are expected to approximate $531,000 and $451,000 for the years ending January 31, 2014 and 2015, respectively. Should the agreement be cancelled, The Association may be subject to cancellation fees contingent on the ability of the rooms to be resold.

The Association also leases certain office equipment under leases expiring at various dates through January 2017.
As of January 31, 2013, net assets are temporarily restricted for the following purposes:

<table>
<thead>
<tr>
<th>Purpose</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research awards</td>
<td>$6,255,022</td>
</tr>
<tr>
<td>Other programs</td>
<td>$2,005,422</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$8,260,444</strong></td>
</tr>
</tbody>
</table>

Permanently restricted net assets includes the beneficial interests in two trusts that The Association does not administer. The investments of each trust are administered by a trustee, who is independent of The Association, and distributions are made to The Association in accordance with the trust agreement for each trust. The beneficial interests in these trusts approximated $684,000 and $657,000 at January 31, 2013 and 2012, respectively.

Permanently restricted net assets also include research endowment principal of approximately $240,000, which is held in perpetuity to generate earnings to support research expenditures.

The Association uses fair value measurements to record fair value adjustments to certain assets and liabilities and to determine the fair value disclosures. The fair value of a financial instrument is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is best determined based upon quoted market prices. However, in many instances, there are no quoted market prices for The Association’s various financial instruments. In cases where quoted market prices are not available, fair values are based on estimates using present value or other valuation techniques. Those techniques are significantly affected by the assumptions used, including the discount rate and estimates of future cash flows. Accordingly, the fair value estimates may not be realized in an immediate settlement of the instrument. The Association groups its assets and liabilities measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.

### FAIR VALUE MEASUREMENTS AT JANUARY 31, 2013

<table>
<thead>
<tr>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assets</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investments in marketable securities</td>
<td>$5,197,117</td>
<td>2,117,170</td>
<td>$7,314,287</td>
</tr>
<tr>
<td>Beneficial interest in perpetual trusts</td>
<td>$970,275</td>
<td>970,275</td>
<td></td>
</tr>
<tr>
<td>Contributions receivable from charitable remainder trusts</td>
<td>207,483</td>
<td>207,483</td>
<td></td>
</tr>
<tr>
<td>Liabilities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annuity payment liability</td>
<td>(788,970)</td>
<td>(788,970)</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$5,197,117</td>
<td>$2,117,170</td>
<td>$388,788</td>
</tr>
</tbody>
</table>
CORPORATE PARTNERS

Total Contributions from Corporations - $1.18 million

$100,000+
BAYADA Home Health Care
Pride Mobility Products Corporation
Sanofi US

$25,000 – $99,999
Avanir Pharmaceuticals
Biogen Idec
ICAP Energy, LLC
Pfizer
Pharmaceutical Research and Manufacturing Association
PostNet

$5,000 – $24,999
Biotechnology Industry Organization
Kaufman, Hall & Associates, Inc.
Merck & Co., Inc.
Occidental Petroleum
Permobil
Vitas Hospice Services, LLC
THE LEGACY SOCIETY

The Legacy Society was established to honor those individuals who, through their generosity of spirit, have included The ALS Association in their long-term financial and philanthropic plans. We gratefully acknowledge their commitment to our core mission of advancing critical ALS research, providing compassionate care services and increased public policy efforts in our ongoing quest for a world without ALS.

Anonymous (27)
Anonymous
in memory of Bernard Johnson
Anonymous
in memory of William J. L’Heureux
Anonymous
in memory of Ross
Anonymous
in memory of my husband, Gary
in loving memory of my father, Henry M. Unger
Anonymous
in loving memory of my mother, Rhea Blaney
Anonymous
in memory of my brother, Dick Carrington
Anonymous
in memory of my grandmother, Margaret M.
Anonymous
in memory of son Frederic
Anonymous
in celebration of the life of my dad, Leonard Dutka
Anonymous
in loving memory of our son, Robert V
Anonymous
in memory of Jack Magennis
Anonymous
in memory of my sister, Gerlinde Lindner
Anonymous
in memory of my parents,
Anonymous
in memory of Mr. and Mrs. Denny Burroughs
Anonymous
in memory of Virginia Duty Burroughs
Anonymous
in memory of my granddaughter,
Anonymous
in loving memory of my son, Robert V
Anonymous
in loving memory of Mrs. Mary T
Anonymous
in loving memory of my wife, Katie
Anonymous
in loving memory of Edward Friedman
Anonymous
in memory of Donna Clark

Arthur H. Barrett†
Dorothy Barth†
Mrs. Margaret A. Beans*
Joe Ann Bearly†
Mr. & Mrs. Avery J. Beer*
Rick Beers*
Dr. Kirk Benson
Rhea M. Berger
Sharon T. Betzelberger*
Terry L. Betzelberger*
Christian Olav Bing
Gary L. and Elizabeth M. Bishop
in loving memory of Alex McKelvey
Rolf F. Bjelland
in memory of Carolyn B. Bjelland
Robert J. Bjorseth*
Ronald J. Blaney
in loving memory of my mother, Rhea Blaney
Eileen Kay Blau
in memory of my beloved husband, Robert W. Smith
Gary and Amy Bobo
in memory of Margaret B. Peugeot
Irene P. Bolton
in memory of Maureen Cantwell, sister-in-law
Doris M. Bongardner
Carol J. Booth and Family
in memory of E.G. Booth
Louis G. Booth†
in loving memory of my wife, Katie
Joan S. Borowsky
Mrs. Michael W. Bowen†
Mr. and Mrs. Schuyler L. Brooks
Andrew T. Brophy
Martha† and Bert† Brown
Mady Brown
in loving memory of my parents,
Rose and Selwyn Cohen
Nelle H. Bruce†
Margaret A. Bruning
Frederick and Elizabeth Burcaw
in memory of Iva Burcaw and Ralph Frederick
Betty J. Burritt†
Mr. and Mrs. Denny Burroughs
in loving memory of Virginia Duty Burroughs
Margaret M. Busch†
in loving memory of my granddaughter,
Stephanie Vetrick Hunt
Mrs. Meta Caliset†
in memory of Vincent Joseph Calise, beloved husband and father
Cape Rider Trust
in memory of Barbara Lee Schneider
John C. Carmody
Mr. John H. Carrington
in memory of my brother, Dick Carrington
Mr. Robert F. Cavedo*
Jayne M. Cawthern
Doris M. Charles
in honor of Richard Charles
Don G. Chatlien
in loving memory of my wife, Doree M. Chatlien
Mrs. Mary Thuss Cheney†
in loving memory of my mother, Gladys F. Thuss
Dr. and Mrs. Richard Chessick
in loving memory of Edward Friedman
Lance Christian
Michael Citrani*
Richard L. “Dick” Clark
in memory of Donna Clark
Joe and Eleanor† Codomo
in loving memory of our son, Robert Vincent
Selwyn S. Cohen†
Beverly E. Collingwood
in loving memory of Alfred A. Keith
Beckie and David Cooper
Christine Creed†
Elizabeth Crossley
in loving memory of my sister, Gerlis Lindner
Will Cutspec†
Barbara Dabul, Ph.D.†
in memory of Jack Magennis
Lauren A. D’Alessandro
in honor Connecticut PALS and families
Ruth S. Dann*
in memory of Elliot W. Dann
The Honorable Jay Daugherty and
Mrs. Lyn E. Daugherty*
Helen K. de Kanter†
Therese Decker
Ellen Dennis
Harold and Elizabeth Dettinger
in honor of Emma Dettinger
Mrs. Haroldyne Dickinson†
in memory of my husband, Howard I. Dickinson
V.E.† and M.H. Dornbach, Jr.*
Charlotte S. Dutka†
in memory of my husband, Les Dutka, with thanks to former patient representative Mary Lyon
Elaine Dutka
in celebration of the life of my dad, Leonard Dutka
Catherine E. Easter
Alfred D. Egendorff†
in memory of son Frederic
Kathleen M. Elkins, Ed.D.
in loving memory of my husband, Robert J. Elkins

* Charter Member / † Deceased
THE LEGACY SOCIETY CONT.

Peggy Ellerton
in memory of my father, Thomas L. Harrell, Jr.

LaVon Eison
in loving memory of my husband, Bernie Eison

Shellat† and Richard Essey∗

Mr. and Mrs.† Glen Ethier∗

Marilyn J. Fall
in memory of Wayne L. Stiede

Evelyn J. Ferngold
in loving memory of my mother, Dana Broomfield Ferngold

Frank Ferrara†

Allen L. Finkelstein

Donald H. Flanders

John F.† and Mary Louise† Fogarty∗

Jane Fosler†
in loving memory of my husband, Keith Fosler

Ruth J. Fox†

Scott Fox
in loving memory of Arthur and Vera Fox

Patricia M. Franks

Mary Kay† and John G. Fry

Howard and Jodie Furbee
in celebration of the life of Velma Zeigler Folck

Floyd Gad†

Robin R. Ganzert
in memory of Michael Aberon

Eugene R. Gardiner

John H. Gauger
in memory of my wife, Sandy

Nancy George
in memory of my beloved husband, Ernest George

Donna Giardina
in loving memory of Pam Maxwell

Marbeth W. Gibson
in memory of Thomas C. Whitney, beloved brother

Jane H. Gilbert

Gillett Family Trust

Roger and Maxifanda Gleckman

Rose B. Gorin†∗

Linda Gottlieb∗

Cynthia A. Greene

Mrs. Jane T. Gregory†∗
in memory of S.L. (Paul) Gregory

The Reverend Joseph Grosko

Karla Sue Gunn and John B. Gunn∗

Elizabeth A. Guon†∗

Barbara M. Hadley∗
in memory of Charles E. Youngman

Herbert A. Hale

Stanley and Maureen Hall
in memory of my wife, Helen Coulthard

Wendy L. Hall
to honor my father, Tyl Hall, who gave me so much love

Terry Halpin∗

Kim A. Hanna

Velma L. Hanson†
in loving memory of my husband, Richard H. Hanson

William A. Harrison, Jr.∗
in loving memory of my life partner, Michael B. Huntley

Philip† and Joan† Hart∗

Michael W. Havlicek∗

Karl W. Helft
in memory of Raquel P. Helft, loving wife and mother

August G. Hiebert†

Jack Hilderbrand∗

Eleanor N. Hill†

Kent Hill
in memory of my wife, Sandra Hill

Chuck and Mares Hirschert
in loving memory of my mother, Margaret Westbrook Hirschert

David and Debra Hirschfeld
in memory of Mary Elizabeth Roché

Alfred J. Hoffman†∗

Emma M. Hohlfied

Mimi Holcombe
in loving memory of my mother, Anne S. Cowie

Marie L. Holle
in loving memory, Clayton R. Demo

Annie M. Holley

Burt Holtzman
in memory of Pauline Holtzman

Ms. Sally Horner

Barbara Hummel
in loving memory of Mark L. Tomchin

Wilbur Hutchins†

Floyd N. Iverson†
in loving memory of my wife, Viola M. Iverson

Kimberly Johnke

Orville E. Johnson†∗

Ray Jordan
in loving memory of my wife, Sally A. Jordan

Mary S. Kassabian

Colonel Jacqueline J. Kelly (Retired)

James and Nancy Kenzik

Rosamond Keough
in loving memory of John J. Keough

John C. Keyes†

John R. Kicklighter
in memory of Vera Mae Kicklighter

Shelley King
in memory of Lynn Smith of Maine

Lynn M. Klein∗

Sherry and Andy Klein

Marvin† and Joan Kloehn

Cynthia Knoche

Dorothy Komarek

Shannon and Joe Konisky
in loving memory of Barry Konisky

Valerie A. Konkle
in memory of my sister, Barbara Konkle Kelly

Marie K. Kovacic†
in memory of my daughter, Katherine Kovacic Dolely

Wilson N. Krahmke

Melanie Krebs

Ms. Andrea Krill
in loving memory of my father, Peter Krill

Cindy La Montagne
in loving memory of my amazing husband, David E. La Montagne, Sr.

Mrs. Mildred N. Landecker
in memory of Dr. Louis Landecker

Peter B. Landecker∗
in memory of Dr. Louis Landecker

Ralph LaPlant

Gordon L. Larsen

Syble Early Lashley
in memory of my mother, Irene Sitton Early

Martha and Brian Law
in loving memory of John Havenden

Hazel M. Lawson†∗

Gary A. Leo

Luis E. Leon
in memory of Clemencia Leon

Kenneth E.† and Barbara J. Levin
in memory of Gail Levin Peterzell

Louis and Jocelyn Libby

Karen K. Lienau
in loving memory of my mother, Thelma C. Kahler

Thelma Lietszan†

John M. Lima
in loving memory of my wife, Emma Sherratt Lima

G. Mary Lincoln
in loving memory of Bob Lincoln

Margaret F. Londt†
in loving memory of my sister Virginia Raubmann

Donald R.† and Mary Lois Long

Sherry Lougheed
in loving memory of my mother, Mildred Erickson Hatton
THE LEGACY SOCIETY CONT.

Dee Dee Lowland
Marjorie MacClean
in memory of Edward W. MacClean
Gloria Salerno Maehl and Gary Maehl
in memory of Dr. Charles Salerno
Nicolas Mares†
in loving memory of Delia, dear wife and mother
Barbara Martin
in memory of my husband, Wayne O. Martin
Leonora O. Masterson
Laila Matthews
Edith Mattmiller†
John† and Denise Matuszewski
John A. Mayott†
Jane L. McBride‡
Rosezell McCarty-Oliver
in memory of Lawrence McCarty
Aubrey McCauley
C. Thomas McClintic and Sandra McClintic
Susan and Kevin McCormack
Ms. Susan McCray*
Laura McCrum†
Doris L. McGowan†
in memory of my husband, Jim
Mrs. Albert McNash
in memory of my husband, Albert H. McNash
Mrs. Mable Messe†
Paul B. Michelet†
in memory of Viola
Tina and Trygve Mikkelsen
in memory of Sheila Essey
Marie A. Mildram
Charles and Nancy Miller
in memory of Stanley Dresden
Donald F. Mills
in memory of my wife, Edna Bauer Mills
Mr. and Mrs. Joseph Miloscia‡
in loving memory and in honor of
Mrs. Patricia Ciccarello
Mrs. James S. Mims
Eileen Mittleman
in memory of my father, Ben Mittleman
Margaret and Walter Molony
Heather and Garry Montag
Maria Montalbano
Randy Vance Morgan
in honor of my mother, Mahaley Sudie Morgan
Annette and Stuart Morris
J. Kent Morrison
in loving memory of my wife, Jeanne Morrison
Karen A. Moschetto
in memory of my uncle, Arthur Johnson
David Moses and Lisa Roberts
Lillian Moskowitz†
Wesley W.† and Lynne E. ‡ Movitz
Louis Mufich
in memory of my wife, Minerva J. Mufich
Mr. and Mrs. Larry Munoz
in memory of my dad, Reuben Munoz, Sr.
Sherry L. Murray
in memory of my husband, CDR Rick Murray, USN (Retired)
Mrs. John W. Musick
in loving memory of my son, Charles Whitley Musick
Mrs. Rena L. Myrick
in loving memory of my husband, F. Guilford Myrick
Evelyn Nasielski
Alice Nedelec‡
in loving memory of Marie A. Nedelec
Anita Nelin†
in loving memory of my husband, William Nelin
Sonja Nelson
honoring Carrie Elenz Layel
Ruth Neuman‡†
Anamarie Neumiller
in memory of my father, Louis B. Neumiller
Gerda Newbower†
Genevieve Newton‡*
for Lowell Newton
Sean Newton‡
for Lowell Newton
Florence R. Neyer
Ken Nicholls
Rodney W. Nichols
Richard A. Nimpie
in memory of Doris E. Nimpie
Earle and Catherine O’Donnell
Lynn C. O’Hara
Doris L. † and John M. † O’Hare‡
Benjamin S. and Dorothy F. Ohrenstein‡
Blanche J. Owens
in memory of my husband, Joseph D. Owens
Elouise Pacitti†
in memory of Robert, loving husband and father
Lauraine Painter†‡
in memory of Edwin J. Painter
Richard Palank
Thomas W. Palmer
Leighton Palmerton
in memory of my wife, Ann A. Palmerton
Mrs. Harry G. Pantages
The Parson+ Family Trust†
in loving memory of Hilda Freese
Catena and Frank Passalacqua
J.R. and Margy Patterson
in loving memory of Linda M. Patterson
Katherine P. Payne†
in loving memory of my brother, Stuart MacMackin
Warner A. Peck ‡
Andrea L. Perr†
in memory of my brother, Geoffrey S. Perr
Mrs. David V. Perry*
John E. Perry, Jr.
in loving memory of Charlotte P. Gromberg
Mary Jo Peyton
in memory of my brother, John E. Peyton, Jr.
Ellyn C. Phillips
Kathleen McGuire Pierce
in memory of six family members with ALS
Anita M. Pollak
in memory of Mercin Channing Pollak
Viola E. Porter†
Lillian B. Potts†
Ramona L. Pressley
in memory of my husband, William F. Brooks, and nieces Karen, Laura, and Susan, and nephew Brian
Rose Marie Proietti
in loving memory of Mark Savory
Robin L. Quigley, Captain U.S. Navy (Retired)
in honor and in memory of Joe Martin
Dean Rasmussen‡
Mary Alice Reddick
Mrs. Martha N. Rees†
in memory of Deacon Paul J. Rees
Bruce† and Sherrie Reid
Margaret V. Reustle
in loving memory of my husband, William
Harry E. Rice, M.D. ‡
Kelli Richmond†
Mary C. Riggs
Mrs. Helen T. and Ms. Jennifer T. Rimerman
in loving memory of Morton W. Rimerman
Carl and Becky Rizzuto
in loving memory of our mom, Antoinette Carvelli
Ms. Jean M. Roldan
in honor of Paulette Gaine
N. Anthony Rolfe
Juan C. Ros
Mr. Richard Rose†
Gerald† and Concetta Ross
THE LEGACY SOCIETY CONT.

Richard S. Roth
Janis M. Rothermel
Jeff Rowe
in memory of Frank Rowe
Richard J. Ryan†
Ronald R. Salbenblatt†
Mrs. Annette Powell Salerno
in memory of Charles, beloved husband
Thomas A. Scammuffa
Carol L. Schaerer
in loving memory of my sister, Robertine Massey Boyer
Robert L. Schenck†
Frances Friedman Schloss
in memory of my late husband,
Justin Friedman
Ben F. Sears
John and Barbara Seibert
Norma M. Shearer†
in loving memory of Ralf De Mouthe
Edythe B. Sheinbaum
in loving memory of my husband, Milton
Judith Shelton
Mrs. Corliss Sherry
my heart, my love—Clayton L. Sherry
Nancy E. Shire
Ruth Shively
in loving memory of my son, Michael Shively
Marilyn Simon-Gersuk and David Gersuk
Mary Smiley
in memory of my son, Steven Smiley
Elliot and Linda Smith
in loving memory of my father, William Wallace Smith
Frances Virginia Smith
Merrill K.† and Hazel P.† Smith
Patricia Snyder and Family
in memory of Thomas T. Snyder
Kirsten Anne Nystrom Snyder and Brandt Edward Snyder
Marion J. Solow†
Theresa Ridgway Soracco
Mr. and Mrs. Robert L. Sorenson*
in memory of Wayne L. Stiede
James O. Speer†
Dr. and Mrs. Charles J. Spengler
Laura and Sarah Stanley
in memory of my mother, Sylvia R. Stanley, and all the members of her family who have suffered from ALS
Karen Starleaf-Abounayan*
Mr.† and Mrs. Gordon F. Stewart*
in memory of Jerome S. Love, M.D.
Ralph R. Stillwagon
in loving memory of Eleanor Stillwagon, dear mom
Elaine F. Stone†
Larry Stough
honoring Carrie Elenie Layel
Clifford E. Strachan*
in loving memory of my wife, Helen Virginia Strachan
James and Prudy Streem Trust
Peter Strugatz*
Gregory M. Stuart
a tribute to my friends who have lived with ALS
Judy Stuart
in memory of my husband, Alan A. Stuart
Glenn Suhr
Ed Sukla
Pauline Sims Swain†
in memory of my friend, Kaziell Poklewski. He lived with ALS for 12 years.
Jerry Taylor
in celebration of the life of Russel Jackson
Maybelle M. Taylor†
in loving memory of Frederick A. Taylor
Steven L. Ross† and Carol L. Thacher*
Kathryn and James Thomas
Lori Tiller
John Timko
Mary Nancy Todd
in loving memory of my mother, Nancy Dunn Procter
Dorothy E. Traviněk
in loving memory of my uncle, Michael Smiles
Judith and David† Travis
Monte Tudor-Long
Marie E. Turianski
in memory of my husband, Gerald W. Turianski
Doug† and Loretta Turner
Elisabeth Twist
Mr.† and Mrs. Roy Uhiman
Mert Urness
in memory of brother Gary A. Urness
Vincent G. Utley*
in celebration of the life of Michael Rice Bertschy
Nancy Van Wyhe
in loving memory of my husband, Conley Van Wyhe
Mr.† and Mrs. Theodore H. Vandling
Frank C. and G. Maxine Vasek*
Rosa C. Vásquez
Electra Venetanosi†
Henry Vera
in memory of my loving wife, Lorraine Vera
Charles H. Viens*
Ellen C. Voie
George W. Wagner†
Robert F. Wallace
in memory of Marilyn Battelli, cherished wife, mother, daughter and beloved sister
Mr.† and Mrs.† Daniel J. Walsh*
Lucille J. Walter
Rev. Charles W. Ward
Renee and Charles, love always/together always
C.J. Ward
Clifford W. Wauters, M.D.†
in loving memory of Helen, beloved wife and mother
Saml† and Karolyn Welty*
Mr.† and Mrs.† Carlyle Whistler
in loving memory of my father, Everett Garrison
Claire Whitaker
in memory of my son, E.F. Wallengren
Jean G. White
in memory of my beloved mother, Marie Griffin, and my loving sister, Elaine Gibler
Ken and Alma Wiegand
in loving memory of Toshiko Densford
Clayton Williams
James S. Williams†
Laural Winston*
in memory of Aunt Ruby and Uncle Bob Harmon
Sharon Wlosek
Mary Sylvia Wolfrey†
in loving memory of my husband, Bill Wolfrey
Harriet M. Wollerstein
Victor L. Wolmer†
Agnes C. Wood†
Darlene Woodall
in loving memory of my mother, Arlene Rushing Lowe
Kenneth Workman and Jennifer Workman
Living Trust
in memory of my beloved uncle, Gilbert Klein, D.D.S.
Katherine M. Wulf†
in loving memory of my dear friend, Floyd V. Algairre
David W. Wurth
Alonzo S. Wyatt†
Patrick M. Ziegenhorn
Mrs. Robert E. Zimmerman†
The Research Council was named in honor of Lawrence R. Barnett, founding chairman of the organization, who became affectionately known as the “grandfather” of The ALS Association for his tireless devotion to finding a cure. We are honored to recognize the distinguished members of the Lawrence R. Barnett Research Council, who are listed below. Through their commitment and generous financial support, our global research program continues its relentless pursuit of treatments and a cure for ALS.

* Charter Member / † Deceased

**VISIONARY**
$20,000 and above

Sally Akin  
_Estate of Gary Wayne Akin_

Lawrence R.† and Isabel† Barnett

Lawrence R. Barnett, Esq.

The Frankel Family  
in memory of Virginia Casey Frankel and Marian Jindra

Kim and Susan Henry  
in memory of Elbert Henry

Bob and Beckie Kevoian  
in honor of Duane Parker

Robert Luongo ALS Fund, Inc.

Edmund G. McCurtain II  
in memory of Edmund McCurtain

Phi Delta Theta International Fraternity’s Iron Phi Program

Helen C. Saults†

Frances Friedman Schloss  
_Barbara Vanderbilt Peck/Justin Friedman Fund for Neurological Research_

Corinne Schwartz  
in memory of Dr. Joel Kleinman

**LEADER**
$5,000 to $9,999

Anonymous

Atkins School District  
in memory of Jennifer Virden-Holley

The City of Avondale Estates

Barbara and Buddy Freitag  
The Neil Brouman, M.D. ALS Research Fund

Elinor M. Georgopulo

Stacey Kors  
in memory of Frances Kors

Pachulski, Stang, Ziehl & Jones  
Harry F. Davis ALS Fund

Mr. and Mrs. Robert Pokelwaldt

Ralphs Grocery Company  
The E.F. Wallengren Fund for ALS Research

Bill Robinson

Eugene and Elizabeth H. Rosenberg  
Rosenberg Research Fund

Edward and Dana Slatkin  
The Neil Brouman, M.D. ALS Research Fund

Ellen Watt  
in loving memory of Gordon Watt

Claire Whitaker  
in memory of my son, E.F. Wallengren

Robert L. Wintemyer, Ph.D., PA-C

**PARTNER**
$1,000 to $4,999

Bruce and Janet Adler  
Rosenberg Research Fund

The ALS Association Minnesota/North Dakota/South Dakota Chapter  
in honor of Sue Spalding

Rene J. Beckham, M.D. and John J. Shufeldt, M.D.  
in memory of Thomas W. Beckham, Ph.D.

Lili and Jon Bosse  
The Neil Brouman, M.D. ALS Research Fund

Joan K. Bower-Oakland†

Mady Brown  
in memory of Rose B. Cohen

Dr. Spencer L. Brown and  
Dr. Lauren C. Pinter Brown  
The Neil Brouman, M.D. ALS Research Fund

Dr. and Mrs. J. Bruijn

Fred and Elizabeth Burcaw  
in memory of Iva Burcaw and Ralph Frederick

Charles M. and Monica A. Burkett†  
in memory of Charles E. Burkett

Marjorie V. Butcher  
in memory of Marie-Claude Minard and in memory of Christian H. Minard

Mark Calmes  
in honor of Jane Calmes

The Gary and Jan Campbell Family Foundation

Kevin and Kathleen Crittenden
John C. Carmody

Sharon F. Chapman
The George Chapman ALS Research Fund,
in memory of George

Cochran Family Foundation

Fred Coffield Fund for ALS

Peter and Jo Cornell
The Neil Brouerman, M.D. ALS Research Fund

Carleton R. Cummings, Jr.
in memory of Barbara "Bobbie" Cummings

Donald Cutler

Alvin and Linda Dietz Fund

Cynthia H. Drollinger

William and Robin Eiland
in memory of Billie P. Eiland

Carolyn Ford Pennington Benevolent Fund

Michal Freedman*

Mr. and Mrs. Robert A. Gay

Dr. Martin G. Giesbrecht
in loving memory of Patricia Berlin

Mary Cornelia Ginn

Drew and Myra Goodman

Peter J. Hackett

Donald R. Hammonds

Joyce C. Harris

Stephen P. Hass
in memory of Harriet S. Hass

Robert V. Hemm, Jr., and Linda D. Hemm

Maynard G. Hine
in honor and remembrance of my dear wife, Bonnie June Hine

Hollywood Charity Horse Show
The E.F. Wallengren Fund for ALS Research

Samuel and Hannah Holzman Trust

Edward and Marcia Horowitz
in memory of Aaron Horowitz and
Marjorie Horowitz Oman

Jay and Delia Jennings
in memory of Rob Marks

Laura Davis Jones
Harry F. Davis ALS Fund

Janet C. Kireker

Howard B. and Susan L. Levy*
in memory of Jack and Phyllis Levy

David H. Lowe, M.D.
in memory of Susan Lowe

Marcia A. Luisi, M.D.
in memory of Michael F. Luisi

Dr. York T. Mandra

Gary Marks
The Neil Brouerman, M.D. ALS Research Fund

Clark H. McGehee
in honor of Robert W. McGehee

Albert Nocciolino
in memory of Emma Nocciolino

Anamarie Neumiller

Thomas K. Ng
in memory of Shan Ng

Allen J. and Lorraine Noveck
in memory of Margaret Noveck

Randy and Karen O'Hare
in memory of David L. (Dec) O'Hare and
Diane P. (Dec) Stone

Bernard Paiiewonsky and Family*
in memory of Sabina Paiiewonsky

Phi Delta Theta-Idaho Alpha Chapter
in memory of our brother, Lou Gehrig

Anita M. Pollak
in memory of Mervin Channing Pollak

Robin L. Quigley, Captain U.S. Navy (Retired)
in honor and in memory of Joe Martin

Dr. and Mrs. S. Michael Roe
in memory of Jack Michael Roe, M.D.

Murray Rothstein
in memory of Jacqueline S. Rothstein

Betty Scharf
in memory of William Scharf

Mark A. Siem and Joan S. Siem
in memory of Shirley Staton

Harry and Sandra Strain
in memory of Art Doyle

Judy Stuart
in memory of my husband, Alan A. Stuart

Brenda Vathauer Slade

Helen F. Weber*
in memory of William C. Weber, Jr.

Michael and Nicole Weis
in memory of Bernell Weis

Anne H. Winks
in memory of Megan Gifford-Foulis

Woodward Family Foundation

Ken and Marie Youngblood
in memory of George J. Pitre

Mary Jane Yue
The Neil Brouerman, M.D. ALS Research Fund,
in honor of Josie and Richard Lee,
in memory of their son, Tommy D.M. Lee
PHILANTHROPY

This report lists the names of individuals, corporations and foundations that made contributions to The ALS Association between February 1, 2012 and January 31, 2013. Every effort has been made to ensure the accuracy of this listing. If your name has been inadvertently omitted or listed inaccurately, please accept our apologies and contact our office at 888-949-2577.

Thank you to all of our donors who supported The ALS Association with a contribution of $1,000 or more, which are listed below:

CORPORATIONS, FOUNDATIONS AND ORGANIZATIONS

Anonymous
Advantage Testing, Inc.
Alliant Energy Foundation
Alpha Delta Pi Foundation, Inc.
Alpha Delta Pi Iota Chapter
Alpha Gamma Rho
ALS Society of Canada
America’s Charities
AquaSid, LLC
Archer Daniels Midland Co.
The Association for Frontotemporal Degeneration
ATG Rehab
Avanir Pharmaceuticals
AYCO Charitable Foundation
Aylward Family Foundation
Bank of America Foundation
Bayada Home Health Care
Edward and June Bernstein Foundation
Beth Shalom of Carroll County
Biogen Idec
Biotechnology Industry Organization
Bluco Corporation
BNY Mellon Community Partnership
Boeing Company Political Action Committee (BPAC)
Booz Allen Hamilton
Bristol-Myers Squibb Company
BTIG, LLC
California Community Foundation
The Capital Group Companies, Inc.
Cars 4 Causes
Charity Gift Certificates
Check Point Software Technologies, Inc.
CNA Foundation
Coles River Club
Comcast / One Comcast Center
Community Foundation of Central Illinois
Community Foundation for the National Capital Region
Community Foundation of New Jersey
Community Foundation serving Richmond and Central Virginia
Cordell Practice Management Group, LLC
Corymore Foundation
Cytokinetics, Inc.
The Alvin & Fern Davis Foundation
Robert E. Dods Family Foundation
The Dodson Foundation
Donna’s Dance....A Studio
Dynavox Systems, LLC
Electric City Running Club
Electromed, Inc.
Employee’s Community Fund of The Boeing Company
Employee's of Northrop Grumman Political Action Committee
Energy & Resource Solutions
ExxonMobil Foundation
Fidelity Charitable Gift Fund
Finger Lakes Skeet League
Flame Enterprises, Inc.
H. Fort Flowers Foundation, Inc.
GE Foundation
Gilbert Unified School District No. 41
Global Impact
Google
The Barbara Vanderbilt Peck / Justin Friedman Fund for Neurological Research of the Greater Cincinnati Foundation
The David and Alan Greene Family Foundation
The Hainer Foundation
The Hurlbut-Johnson Fund
IBM Corporation
IBM Employee Services Center
ICAP Energy LLC
Iglesiiski Family Foundation
ING
Inner Space Constructors
Ixis Pharmaceuticals, Inc.
The J2 Foundation
The Nathan P. Jacobs Foundation
Johnson & Johnson
JustGive.org
Kaufman, Hall & Associates, Inc.
Knopp Biosciences LLC
The Jack and Dorothy Kupferberg Family Foundation
LA-CO Industries, Inc.
LC Technologies, Inc./Eyegaze Systems
LD Commodities Portland LLC
Lee Brothers Inc.
Lee Mendelson Productions, Inc.
LegacyTree Foundation
Annette M. and Theodore N. Lerner Family Foundation
Lifetouch Inc.
Lozier Foundation
Macquarie Bank Foundation Limited
Martin Health System
The McIntosh Foundation
Merck Partnership for Giving
Michael Baker Corporate Foundation
Microsoft
MUSC Pharmacy School Class of 2012
National Philanthropic Trust
NCI Information Systems, Inc.
The Neeb Family Foundation
Neshaminy High School Drama Club
Network For Good
Occidental Petroleum Corporation
Olson/Kotowski, Inc.
The Oppenheim Family Fund
The Pattis Family Foundation
Pepsico Foundation
Pfizer Foundation
Pfizer Inc.
Pharmaceutical Research and Manufacturing Association
Phi Delta Theta—Illinois Gamma Chapter
Phi Delta Theta—Kansas Zeta Chapter
Phi Delta Theta—Maryland Alpha Chapter
Phi Delta Theta—Maryland Gamma Chapter
Phi Delta Theta—Mississippi Beta Chapter
Phi Delta Theta—Missouri Alpha Chapter
Phi Delta Theta—Ohio Beta Chapter
Phi Delta Theta—Ohio Mu Chapter
Phi Delta Theta—Oklahoma Beta Chapter
Phi Delta Theta—Oregon Beta Chapter
Phoebe Snow Foundation
Planet Green
The Platt Foundation, Inc.
The Polk County Community Foundation, Inc.
PostNet
Pride Mobility Products Corp.
Quest Diagnostics
Renaissance Charitable Foundation, Inc.
Richard Stravitz Gallery LLC
Roll Giving
The Irene Herbert Ross and Harper Grant Ross Foundation
SA Services LLC
Sanofi Aventis U.S.
Geoffrey and Susan Schmidt Foundation
Schwab Charitable Fund
The Thomas H. and Mayme P. Scott Foundation, Inc.
Sempra Employee Giving Network
Shugart Family Foundation
Fred Siegel Foundation
Silicon Valley Community Foundation
The Southern League of Professional Baseball Clubs, Inc.
Stand Aid of Iowa, Inc.
Stuart Steel Protection Corp.
Everett D. & Geneva V. Sugarbaker Foundation
Swiss Re
Synapse Biomedical Inc.
Louis F. & Mary A. Tagliatela Foundation
TechSoup Stock
Therm-Omega-Tech Inc.
Time Warner Cable
TisBest Philanthropy
TMI—The Episcopal School of Texas
Tobii Assistive Technology, Inc.
Tropham Foundation
Truist
United Jewish Foundation of Metropolitan Detroit
United Stationers Charitable Foundation
Vanguard Charitable Endowment Program
Vera Bradley
The Vermont Community Foundation
Visa Givingstation
Vitas Hospice Services, LLC
VMware Foundation
The Edgar V. Weir Family Foundation
Westampton Education Association
The Harold Wetterberg Foundation
Wittenberg University
Worcester Academy
ZBI Employee Allocated Gift Fund

INDIVIDUALS
† Deceased
Anonymous (2)
Thomas W. Abendroth and Terri L. Mascherin
Carolyn F. Adelsten
Leah Alfonso
Dawn M. Algrim
Rene Alkoff
Chad and Sami Amonsson
Dorothee P. Angel
Andrew J. Ashton
Barbara R. Ball
Jennifer Ballenger
Otts Ballenger
Lester Baltimore
Lawrence R.† and Isabel† Barnett
Lawrence R. Barnett
H. R. and Doreen Barr
Deborah Bass
Michael Batnick
Sharon D. Bell
Nancy Berkovitz
Josh M. Berman
Jay and Pamela Bieber
Michael Bisceglia
Cristina Bita
Robert B. Bjorseth
Gene and Danell Bleymaier
C. James and Carole Bluhm
Brett Boege
Brion Brandes
David G. Brandt
Robert Brooks
Tracy L. Brooks-Szegda
Heather A. Brown and Matt Brown
Karen S. Brown
Robert H. Brown, Jr. and Elaine Beilin
Chris W. Brussalis
Mrs. J. Mahlon Buck, Jr.
Michael Buratti
William and Janene Burke
Samuel Burton
Steve Byrd
Matthew T. Caddell
Michele Capps
Emanuel and Joan Carreras
Charles and Michele Carroll
Margaret A. Carver
Richard Chadakoff
Ann M. Chioles
Harris Chung
Joseph Cipriano
Donald K. Clark
Scott Cohen
Stephen and Nancy Cohen
Paul Colasanti
James and Margaret Coleman
John and Janet Collins
Terrie D. Combs
Chris and Janice Commons
Gary J. Connell
Will Conniff
Cathy Z. Cordisco-Emanuelson
Richard and Bunny Corey
Joseph and Sandra Corish
J.R. and Mitzie Craddock
Nancy Crockett
Neil and Mary Joe Crosby
Lisa Cuff
John and Deirdre Dabney
Elizabeth Daitch
Robert First
Bernadine Flickinger
Mark M. Foster and Nancy K. Koehler
Michael R. Foster
Richard and Lynn Frankel
Mark and Aileen Friedlein
Betty J. Fritz
Cynthia Garretson
Jack Gendzel
E. Norman and Suzanne George
Michael and Alecia Gersh
Jane H. Gilbert
Tim Glocker
Larry C. Glotfelty and Tracy L. Glotfelty
Roberta Goin
Earl and Aya Goldberg
Martin and Sandra Goldstein
Stan Goldstein
R.C. and Connie Gonzalez
Russell and Kathy Gottfried
Anthony Grande
Mr. and Mrs. William T. Hammonds
George and Kathleen Hardart
Edwin and Linda Hartz
Mr. and Mrs. Pierre D. Hayward
Edith S. Heckman†
Robert J. Hemmig
Mr. and Mrs. Donald Herman, from the
John & Rose Herman Support Foundation
Donald and Bluma Herman
Susan E. Hermann
Joyce A. Hill
Lawrence and Margaret Hinders
Sherman and Pamela Hixon
Betty Hoffman
Matthew and Cindy Hogge
Wayne Hoovestol
Doris Horner
Kevin and Patricia Houlihan
Michael J. Howes
Eric W. Hoyt
Joe B. Hudgens
Kenji Iijima
Mark and Jane Ivanick
Brendan Jacksits
James A. Jahn, Jr.
Jeff Jones
Linda Joost
Judy A. Jorge
Andrew and Elizabeth Jurgenson
Bill Jurney
Susan Kaiser
George Karnoutsos
Roy Kaufmann
Dan and Nancy Kennedy
Dan and Margie Kernen
Richard and Gloria Kerns
Mary A. Kim
Franklin and Collette Kitto
Sapna Kuchuparambel
Edgar and Eileen Koerner
Matthew B. Koll
Viola Kranenberg
Bryce Kranzthor and Nancy Griffin
Joanne Kranzthor
John Kugler
Joseph and Nancy Kunkel
Charles Lamont
Paul Lang
Norma L. Laubhan
Douglas Lavallée
Virginia Leitch
Gary A. Leo
Richard E. Leonardon
Jeffrey and Joyce Levine
Ben Lewis
Steve J. Lindo
Gary and Judy Lohmeyer
Cristina Lombardo
Joanne Lotreck
Joan B. Loving
Larry L. Luing
Theodore D. Lynch/The Lynch
Charitable Fund
Mary Lyon
Leslie MacNeil
Gloria Salerno Maehl and Gary Maehl
Kimberly Maginnis
Heidi Magner
Eric Maier
Richard Maizel
Wendy Manning
Kate Mansergh
Todd and Felice Marcy
Maura Marczewski
Thomas L. Martin
Mrs. Russell (Marjorie J.) McChesney
Richard and Francesca McCleary
Janet M. McClelland
Christopher and Jeanne McCoy
Daniel McDermott
Linda D. McFarland
PHILANTHROPY CONT.

Richard and Beth McLaughry
Marney Mesch
Greg Miller
Peter Miller
Nedra R. Mise
Jose Moreno
John and Margaret Morgan
Allison Muentener
Louis Mufich
Ruth Murphy
James and Kandice Murray
Sean Murray
Thomas E. Myers
John and Michelle Neeb
Michael Newman
Terence Nicol
Albert I. Niemeyer
Alice Noll
Stuart and Marcia Obermann
Philip and Laureen O’Larey
David and Jamie Oliver
Gary Olsen
Daniel J. O’Neill
Timothy O’Toole
Thomas W. Palmer
Martha M. Parke/The Parke Charitable Fund
Stephen Parr
Jeff and Mary Patton
Mr. and Mrs. Gordon R. Pellerin
Joseph Robert Portmann III/The Portmann Family Charitable Fund
Howard S. Potter, Jr.
Gregg S. Powell
Rose Marie Proietti
Tanya Quinn
Nasrin F. Rahat zad
Bill and Angela Ramey
JoAnn Ranck
Sedell G. Rand
Dale and Carol Rasmusson
Chris Rath
Jim Ream
Tony N. Redd
Nancy L. Reinen
Kathy Reynolds
Michael and Anne Rhoads
Timothy and Barbara Riauzzi
Shane and Robin Robison
Bobbiedine Rodda
Parker O. Roe
Nancy D. Rosan
Carol Rosenberg
Eugene and Elizabeth H. Rosenberg
John and Barbara Rothhaar
Murray Rothstein
Sharon M. Rowlen and Craig Rowlen
Richard C. Ruggeri
Thomas R. Ryan
Paul Ryken
Robert Rynalski
Nelson Saires
Dan and Sara Sapadin
John and Dorothee Sargent
Patricia P. Savage
Michael Saxon
Thomas P. Scanlan
Gwyneth M. Schultz
Mark B. Schupack
Esther K. Schwartz
Mildred Schwartz
Neil F. Schwartz
Robert and Elizabeth Scott
Michael and Renita Seldowitz
Tracy and Helen Selmon
Mark Shacket
Lisa Sharp
Victor and Liliana Shen
Jason R. Shonk and Jennifer Randle
Mark Siebert
Samantha Siegel
Howard and Robyn Silk
Michael and Abbey Silver
Donnie and Jacquelyn Silverman
William Peter Sipe and Joyce Sipe
Jerry Skinner and Ann Cody
Lee and Cynthia Small
Gene Smith
Kevin and Laurel Smith
Edgar and Sandra Snyder
Andrew and Jane Soffel
William Soffel
Michael R. Spell
Robert and Sylvia St. Jean
Keith and Vickie Stamler
Rudolph Steiner
Diane F. Stephens
Barry Strugatz
Jan H. Suwinski and Susan Suwinski
Rebecca C. Swan
Lara Swenson
Joseph and Ellen Tessitore
Quinn Thompson
Ann E. Titzer
Allan J. Tobin
Joseph and Toshiko Tompkins
Stephen and Lawson Travers
William and Jeanne Tyler
Rhonda J. Uhlenbrock
Blanche Underwood
Elise M. Upchurch
Robert Van Iten
Robert C. Verrett
Larry and Marianne Wagoner
Ira J. Wagner
William and Peggy Wainscott
Natalie and Larry Wassong Charitable Fund
Douglass S. Watson
John R. Wendel
Frederic Westendorf
Paul and Erika White
Jeffrey and Jennifer Whitehorn
Bernd and Frances Wiehn
Terry and Colleen Wilkins
Sabin Willett and Marta Willett
Timothy Wilson
Linda W. Windsor
Fredrick M. Wiste
Susan Wood
Gilbert D. Woolridge
Deborah Woodward
Frances F. Wurlitzer
David M. Yocum
David Zaunbrecher
Dean A. Zerbe
**LEADERSHIP**

**TRUSTEES**

**Lawrence R. Barnett**  
The ALS Association Chairman Emeritus

**The Hon. Jay Daugherty**  
The ALS Association Chairman  
Shaffer Lombardo Shurin  
Kansas City, Missouri

**William Thoet**  
The ALS Association Vice-Chairman  
Senior Vice President  
Booz Allen Hamilton  
Herndon, Virginia

**Luis Leon**  
The ALS Association Treasurer  
Retired Chief Executive Officer  
Royal Caribbean Cruises, Ltd.  
Miami, Florida

**Douglas Butcher**  
The ALS Association Secretary  
CBRE/Louisville  
Louisville, Kentucky

**Lawrence R. Barnett, Esq.**  
Gipson, Hoffman & Pancione  
Los Angeles, California

**Phyllis R. Brouman, Esq.**  
Beverly Hills, California

**Chris Brussalis**  
President and CEO  
The Hill Group, Inc.  
Carnegie, Pennsylvania

**Daniel deGrandpre**  
Chief Executive Officer  
dealnews.com  
Madison, Alabama

**Cynthia D. Douthat**  
Atlanta, Georgia

**Robin R. Ganzert, Ph.D.**  
President  
American Humane Association  
Washington, D.C.

**Wilson N. Krahne**  
Chevy Chase, Maryland

**Edmund G. McCurtain, II**  
Boulder Creek, California

**Kim Ann Mink, Ph.D.**  
Global General Manager, Elastomers  
Dow Chemical Company  
Midland, Michigan

**Timothy O’Toole**  
Chief Executive Officer  
Vitas Healthcare Corporation  
Miami, Florida

**Ellyn C. Phillips**  
Chair  
The ALS Association Greater Philadelphia Chapter  
Ambler, Pennsylvania

**Jonathan Roberts**  
Executive Vice President and Chief Operating Officer  
CVS Caremark  
Lincoln, Rhode Island

**Elizabeth Heller Rosenberg**  
Director  
Haworth Library  
New York, New York

**William D. Soffel**  
President  
Vacation Properties Realty, Inc.  
Chautauqua, New York

**Chris Stevens**  
Vice President Corporate Relations and Customer Development  
Keurig, Inc.  
Wellesley, Massachusetts

**Allan Tobin, Ph.D.**  
CHDI Foundation  
Los Angeles, California

*Executive Committee Members*
CHAIRMAN’S COUNCIL

Robert V. Abendroth, Esq.
Whyte Hirschboeck Dudek S.C.
Milwaukee, Wisconsin

Robert J. Bjorseth
Tech Inc.
Lenexa, Kansas

Andrew T. Brophy
Brophy Properties, Inc.
Washington, D.C.

Richard P. Essey
Chairman
TemPositions
San Francisco, California

Allen L. Finkelstein, Esq.
Pavia & Harcourt
New York, New York

Alan R. Griffith
Centreville, Maryland

William G. Matthews
Retired Vice President Sales
3M
St. Paul, Minnesota

Benjamin S. Ohrenstein, Esq., CPA
Haverford, Pennsylvania

Lawrence A. Rand
Senior Vice President
Kekst and Company
New York, New York

Howard B. Safenowitz, Esq.
Calabasas, California

Stephen H. Saltzman
North Bergen, New Jersey

Kenneth Wiegand, Jr.
Retired Senior Vice President
Booz Allen Hamilton
Herndon, Virginia

Laural Winston
Retired Chief Financial Officer
TECHMER PM
Palm Desert, California
NATIONAL OFFICE EXECUTIVE STAFF

Jane H. Gilbert  
President and Chief Executive Officer

Dan Reznikov  
Chief Financial Officer

Stevan Gibson  
Chief Public Policy Officer

Michelle Keegan  
Chief Development Officer

Kimberly Maginnis  
Chief Care Services Officer

Carrie Martin-Munk  
Chief Communications and Marketing Officer

Ken Nicholls / Lance Slaughter  
Chief Chapter Relations Officers

Lucie Bruijn, Ph.D.  
Chief Scientist